Life Science Connect Blog

1. What Is Going To Be The Next Big Thing For Biopharma In 2016? 1/4/2016

   There are plenty of industry insights available, such as Life Science Leader’s comprehensive December 2015 Outlook issue for 2016 or our four-part trendsetter series. And while these provide a wealth of insight, I felt compelled to put together one last blog to prevent you from being blindsided by the “Next Big Thing” in biopharma in 2016.

2. How Can You Provide Healthcare Value In A Patient-Centric Era? 10/1/2015

   Patients have become more empowered, better informed, and more financially invested in their health and well-being than ever before. As a result, we have seen the healthcare landscape evolve toward a patient-centric delivery model.

3. Does Being Disruptively Innovative Translate Into Being More Patient-Centric? 9/25/2015

   Everyone has experienced poor customer service in one form or another. Say you want to call a company with a question or a complaint about a product. You’re likely to be informed by an automated voice that, “Due to the high volume of calls we are currently experiencing, your anticipated wait time will be X minutes.  For faster and more convenient customer service, please visit our website at www.wedon’tcaretospeaktoyou.com.

4. How To Build A Corporate Culture Of Sustainable Innovation 7/27/2015

   Shortly after the April 2015 publication of Guiding Bayer’s Global Innovation Engines To New Heights, an article I wrote featuring Bayer board of management member, Kemal Malik, I received a phone call from Valerie Bowling. The executive director for the Conference Forum and producer of one of my favorite events, Disruptive Innovations to Advance Clinical Trials (DPharm), Bowling said the article sparked an idea.

5. FDA News Roundup: Otsuka, AstraZeneca, Ipsen, And More 7/17/2015

   What FDA decisions have you missed recently?

6. Venture Philanthropy: Is It Really Promoting Patient Centric Drug Development? 7/14/2015

   Within the last 10 years, a number of nonprofit groups, including the Michael J. Fox Foundation and the Multiple Myeloma Research Foundation, have taken a similar approach to ensuring that their targeted patient populations are being well represented in pharma R&D.

7. FDA News Roundup: Pfizer, Eli Lilly, Vertex, And More 7/10/2015

   What FDA decisions have you missed recently?

8. Is Pharma Truly Equipped For Transparency? 7/8/2015

   As the call for transparency grows louder in the pharma industry, the question arises: are drugmakers equipped with all they need to be transparent — especially when it comes to demonstrating their drugs’ economic value?

9. Will Biotech Employment Continue To Rise As The Industry Evolves? 6/30/2015

   A report from the Bureau of Labor Statistics found that nationwide employment in “pharmaceutical and medicine manufacturing” sunk from 291,795 in 2003 to 277,113 in 2013, The Philadelphia Inquirer reported recently. But it’s not the same story for biotech R&D: employment hit 142,475 in 2013 — up from 135,424 in 2007.

10. Does Adversity Build Character Or Reveal It? 6/12/2015

    Denice Torres is the president of McNeil Consumer Healthcare, a Johnson & Johnson company, and winner of HBA’s 2015 WOTY award. Listening to her acceptance speech reminded me of legendary pro football coach Vince Lombardi’s philosophy — “Adversity doesn’t build character, it reveals it.”